Efficacy of Anidulafungin in the treatment of invasie candida infections in clinical practice

Efficacy of Anidulafungin in the treatment of invasie candida infections in clinical practice - Anidulafungin

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00000074

Enrollment

Registered

2009-01-27

Start date

2009-03-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

invasive Candidiasis infection B37

Interventions

Group 1: treatment according marketing authorisation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: invasive mycosis through candida species

Exclusion criteria

Exclusion criteria: Treatment is compliant with approval of Anidulafungin.

Design outcomes

Primary

Measure	Time frame
- ongoing (< 7 days) improvement with regard to underlying disease after donation of Anidulafungin - two negative blood analysis (3-7 days after start with therapy with Anidulafungin, samples to be collected with intervall of 24 h) in case of candidae or no evidence or agent persistence after end of therapy - no necissity to change of antimykotic therapy after within 7 days of start after Anidulafungin treatment	—

Measure

Time frame

- ongoing (< 7 days) improvement with regard to underlying disease after donation of Anidulafungin - two negative blood analysis (3-7 days after start with therapy with Anidulafungin, samples to be collected with intervall of 24 h) in case of candidae or no evidence or agent persistence after end of therapy - no necissity to change of antimykotic therapy after within 7 days of start after Anidulafungin treatment

—

Countries

Germany

Contacts

Public ContactWinfried Kern

Universitätsklinik Freiburg Sektion Infektiologie Medizinische Klinik II

winfried.kern@uniklinik-freiburg.de+49 761 270 1819

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026